Derick Cooper
Chief Executive Officer
Derick Cooper worked with QOL Medical as Chairman of the Board from 2003 to 2010, and recently increased his operational responsibilities with QOL Medical as CEO. Prior to 2010, Mr. Cooper managed private equity investments for Cooper Capital, a Southeast-based private equity fund with a focus on $2mm to $10mm investments. Mr. Cooper also served as the Chairman of the Board for Courtesy Outdoor Finance. Prior to Cooper Capital, he spent ten years in investment banking, mergers and acquisitions, venture capital, corporate finance and operations and management with The Robinson-Humphrey Company in Atlanta, as a portfolio manager with Sirrom Capital, formerly the largest mezzanine lender in the US, and with CooperSmith, formerly the largest independent baked foods company in the US. Mr. Cooper graduated cum laude from Washington and Lee University with a B.S. in Business Administration.

William M. Dupere
Chief Operating Officer
Prior to joining QOL Medical as COO in 2010, William Dupere spent twenty years in a variety of pharmaceutical operational and consulting capacities with companies such as GSK, Eli Lilly, Genentech, Amgen, Sanofi and US Oncology. Mr. Dupere's operational focus was primarily on new product launches through initial commercialization with products such as Gemzar, Herceptin, Rituxan and Eloxatin. Mr. Dupere has experience in designing product management plans in clinical, regulatory, commercial launch and reimbursement. His background in clinical trial design includes four PMA submissions, and he also has experience in specialty pharmacy distribution and management. Mr. Dupere is a graduate of the University of North Carolina with an undergraduate degree in Public Health and an MBA.

William V. Bryant
Chief Financial Officer & General Counsel
William Bryant, CFO, has broad experience with small business planning, growth and development and in assisting small- to medium-sized businesses in financing that growth. He has practiced as a CPA for fifteen years and as an attorney for over twenty years, specializing in business financing, growth and management, and in mergers and acquisitions transactions. He was a member of the management team of CooperSmith, Inc., formerly one of the largest independent baked foods companies in the US, assisting in its aggressive acquisition program as well as its daily operational needs. Mr. Bryant was formerly an associate working on raising capital and significant M&A transactions with large public companies with Jones Day, one of the largest law firms in the world. Mr. Bryant graduated magna cum laude from the Georgia State University College of Law and earned his Bachelor of Business Administration degree from Valdosta State University.

Dayton T. Reardan, PhD, RAC
Vice President of Regulatory Affairs
Prior to joining QOL Medical in 2011, Dr. Reardan served as Vice President of Regulatory Affairs for Eleos Inc. as well as Orphan Medical Inc., and as a Director at CV Management Therapeutics and Xoma Corporation. During the eleven years Dr. Reardan was head of regulatory affairs at Orphan Medical, the firm was successful with all regulatory filings in the US, Europe, Japan, Middle East, and Canada, obtaining initial marketing approval from the U.S. FDA for eight products and three major efficacy supplements expanding indications. These marketing authorizations included five new chemical entities. These approvals have been for public and private corporate entities primarily in the field of Orphan Drugs, both domestically in the United States and abroad. Dr. Reardan has led regulatory registration teams for a total of thirteen approvals to date, and has submitted over thirty successful INDs. In 2011, Dr. Reardan’s twenty-third patent was issued. In addition to his regulatory responsibilities, Dr. Reardan has also managed manufacturing, quality control, quality assurance and intellectual property for many of his client firms. He earned his doctorate in physical chemistry from the University of California at Davis with a thesis on cancer related monoclonal antibodies and is regulatory affairs certified.